Abnova - VHH nanoBiTE™ Service
Fc-Free Bispecific VHH Antibody Engineering Platform for Targeted Immunotherapy
Abnova’s VHH nanoBiTE™ service specializes in the development of bispecific VHH antibodies—compact, engineered molecules capable of binding two distinct antigens or epitopes simultaneously. This dual-targeting ability is ideal for immune and tumor cell redirecting, multiple epitope targeting, and novel immuno-oncology research.
Their small molecular size allows deep tissue penetration, making them especially effective in hard-to-reach areas like the tumor microenvironment. The absence of an Fc domain eliminates Fc receptor interactions, reducing off-target immune activation and enabling precise therapeutic action.
Each VHH nanoBiTE™ is constructed by genetically fusing two VHH domains with a flexible linker, combining high-affinity binding with reduced production complexity—delivering a powerful, modular platform for next-generation biologics.
Advantages
- Small Size
- Superior Stability
- High Affinity and Specificity
- Easy Conjugation
- Enables Rapid Immune Cell Activation While Minimizing Systemic Exposure
- Cost-Effectiveness and Scalable Production
Workflow
Data Examples
Indirect ELISA
Indirect ELISA Analysis of 2X diluted culture supernatant & purified human PD-L1 x CD3e nanoBiTE™. Human PD-L1 hFc fusion protein was coated onto a plate. 2X diluted culture supernatant and purified human PD-L1 x CD3e nanoBiTE™ were used as the primary antibody, with rabbit anti-Camelid VHH Cocktail (HRP) as the secondary antibody.
Sandwich ELISA
Sandwich ELISA Analysis of human PD-L1 x CD3e nanoBiTE™. Goat Anti-Human IgG-Fc was coated onto a plate as the capture antibody and incubated with human PD-L1 hFc fusion protein . Human PD-L1 x CD3e nanoBiTE™ was serial diluted as the detection antibody, with rabbit anti-Camelid VHH Cocktail (HRP) as the secondary antibody.
Flow cytometry
A. Flow cytometry analysis verified the effective binding of human PD-L1 x CD3e nanoBiTE™ to enriched human CD8 T cells from healthy person, serving as the CD3e positive control.
B. Flow cytometry analysis verified the effective binding of human PD-L1 x CD3e nanoBiTE™ to HT29 cells, serving as the PD-L1 positive control.
